Skip to main content
Premium Trial:

Request an Annual Quote

Sandia Scientists Win Processing Time on DOE Supercomputer

NEW YORK (GenomeWeb News) — Two researchers at Sandia National Laboratories have been awarded processing time on Oak Ridge National Laboratory's Cray XT supercomputers to simulate complex biological membranes for use in disease studies.

Under the Department of Energy's Novel Computational Impact of Theory and Experiment, or INCITE, award, the Sandia researchers will have one million processor hours on ORNL's machines, the Albuquerque, NM, lab said today.

Sandia researchers Mike Heroux and Laura Frink will use the ORNL systems to try to gain knowledge about how diseases penetrate lipid bilayers that could be useful in developing new disease treatments. They will focus on the role of antimicrobial peptides, which "are known under some conditions to be lethal to bacteria, yet under other conditions cause increased membrane permeability," Sandia said.

INCITE awards are selected by DOE's Office of Advanced Scientific Computing.

Sandia is operated by the Lockheed Martin subsidiary Sandia Corporation for the DOE's National Nuclear Security Administration.

Filed under

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.